

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the specification:

Listing of Claims

1. (original claim) Tamsulosin hydrochloride, ((R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxybenzenesulphonamide) hydrochloride, in the amorphous form.
2. (original claim) Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the DSC thermogram thereof exhibits an exothermic peak at about 100 °C.
3. (original claim) Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the IR spectrum thereof exhibits a band at about 3449 cm⁻¹.
4. (original claim) Tamsulosin hydrochloride in the amorphous form according to claim 3 characterised in that the IR spectrum thereof exhibits the bands substantially as shown in Table 1.
5. (original claim) Tamsulosin hydrochloride in the amorphous form according to claim 1 characterised in that the X-ray powder diffractogram thereof exhibits the absence of discrete diffractions which are characteristic of crystalline forms.
6. (original claim) A process for the preparation of the amorphous form of tamsulosin hydrochloride characterised in that it comprises lyophilization of a solution of tamsulosin hydrochloride.
7. (original claim) The process for the preparation of amorphous tamsulosin hydrochloride according to claim 6 wherein said solution of tamsulosin hydrochloride is aqueous solution.
8. (canceled)
9. (original claim) The process for the preparation of amorphous tamsulosin hydrochloride according to claim 8 wherein said solution of tamsulosin hydrochloride is aqueous solution.
10. (original claim) A pharmaceutical formulation comprising tamsulosin hydrochloride and one or more pharmaceutically acceptable excipients characterised in that it comprises tamsulosin hydrochloride in the amorphous form.
11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)